You are currently viewing Cordis and Medinol Announce First U.S. Commercial Implants of Innovative EluNIR™ Drug-Eluting Stent

January 11, 2018 – Cordis, a Cardinal Health company, and Medinol  announced that the first commercial cases using the EluNIR™ drug-eluting stent (DES) in the United States were performed at New York-Presbyterian Hospital/Columbia University Medical Center in New York City and the Piedmont Heart Institute in Atlanta.

“Our first patient cases with the EluNIR™ stent went perfectly and we are enthusiastic about the overall performance including the uniform vessel coverage and the delivery system with the metallic spring tip, which is unlike any other product in the market,” said Martin B. Leon, M.D., director of the Center for Interventional Vascular Therapy at the New York-Presbyterian Hospital/Columbia University Medical Center. “I have been following Medinol for over 20 years and am excited to see yet another one of the company’s innovative products launch in the U.S. market.”

The EluNIR™ stent was approved for the treatment of patients with narrowing or blockages to their coronary arteries and is now being distributed to cath labs in the U.S. by Cordis. The EluNIR™ stent system is designed to help clinicians easily deliver this new DES in highly complex anatomy and disease and offers a novel metallic spring tip and the narrowest strut width of any stent on the U.S. market.

“The physicians and staff at Columbia and Piedmont have played pivotal roles in the evolution of the EluNIR™ stent,” said Dr. Yoram Richter, chief scientific officer at Medinol. “We are honored to have the first commercial cases with EluNIR™ performed at such notable institutions. This event marks another step in Medinol’s legacy, which has continued to stretch the limits of innovation, starting with our NIR stent in 1996.”

Cardinal Health and Medinol entered into a long-term distribution agreement that gives Cordis, Cardinal Health’s interventional vascular business, the rights to sell Medinol’s coronary stent portfolio, which now includes the EluNIR™ DES and NIRxcell™, a cobalt-chromium bare metal stent (BMS), in the U.S.

“We are confident that the novel stent and delivery system of the EluNIR™ DES will offer ease of delivery, especially in highly complex cases,” said Luis Davila, vice president of R&D at Cordis. “Cordis is committed to bringing new technologies, like EluNIR™, to the market to provide even more treatment options for clinicians and their patients affected by coronary artery disease.”

About MedinolMedinol is dedicated to the science of cardiovascular intervention. For over 20 years, Medinol‘s in-house research, development, and manufacturing have continuously raised the bar for quality and performance of stenting systems. With over two million stents delivered to date, Medinol‘s cutting-edge cardiovascular intervention technology continues to demonstrate extraordinary clinical results, and our products constantly stretch the limits of innovation. Medinol develops, manufactures, and markets EluNIR™, the first elastomeric drug eluting stent. Made from thin cobalt-chrome alloy and recognized for its unique flexibility, conformability and scaffolding, EluNIR offers new level of uniform drug elution and surface quality, and demonstrated excellent clinical outcomes and promising safety profile in two clinical studies.

About Cordis – Cordis is a worldwide leader in the development and manufacture of interventional vascular technology with a more than 50-year history of delivering pioneering products to treat millions of patients. With a reputation for clinical acumen, training and services, Cordis established a legacy of innovation in high-quality and less-invasive cardiovascular products and built a strong global footprint with operations in countries around the world.

About Cardinal Health – With nearly 100 years of experience, Cardinal Health helps pharmacies, hospitals and ambulatory surgery centers, clinical laboratories and physician offices focus on patient care while reducing costs, enhancing efficiency and improving quality. Cardinal Health help pharmacies, hospitals and ambulatory surgery centers, clinical laboratories and physician offices focus on patient care while reducing costs, enhancing efficiency and improving quality. We operate the nation’s largest network of radiopharmacies. Cardinal Health provides medical products and services to many of America’s most prestigious medical institutions. In fact, most U.S. hospitals use our products and services to provide care for their patients. And, now we’re making this same quality and exacting standards of performance available to patients through products that help provide affordable healthcare at home.

Source –